Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active Surveillance for Low Risk and Carboplatin vs. Cisplatin for Standard Risk Germ Cell Tumors
NCT03067181Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- May 2017
- Primary completion
- Jun 2027
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 9
01
Overview
A Phase 3 trial of carboplatin, Cisplatin micelle injection (HA132) in germ cell tumor (GCT), sponsored by Children's Oncology Group. Started May 2017; status: recruiting.
02
Drugs
carboplatinCisplatin micelle injection (HA132)
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03067181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067181.